In a rare blockbuster performance for AstraZeneca, Tagrisso comes through on lung cancer PhIII
For a Big Pharma company that often gets things wrong, Tagrisso has been AstraZeneca’s ace in the hole. Sped through the clinic to a first approval in an astonishing two years, it was already on the market when Clovis’ rival imploded on arrival at the FDA.
Today, the pharma giant is pulling back the veil off of new data demonstrating a 5.7-month improvement in progression-free survival of non-small cell lung cancer among patients with an epidermal growth factor receptor (EGFR) T790M mutation compared to platinum-based doublet chemotherapy (10.1 months vs 4.4 months). And the PFS spread significantly favored Tagrisso among the one-third of patients with CNS metastases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.